Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision Next revision | Previous revision | ||
|
group_1_presentation_1_-_breast_cancer [2017/10/06 17:37] trana27 [Pathophysiology] |
group_1_presentation_1_-_breast_cancer [2018/01/25 15:19] (current) |
||
|---|---|---|---|
| Line 1: | Line 1: | ||
| ======= Breast Cancer ======= | ======= Breast Cancer ======= | ||
| + | |||
| + | Powerpoint file: {{:a-look-inside-breast-cancer-1.pptx|}} | ||
| ===== Introduction ===== | ===== Introduction ===== | ||
| Line 212: | Line 214: | ||
| === Immunotherapy === | === Immunotherapy === | ||
| - | Current research has progressively contributed to the advancement of breast cancer treatment. The investigations have been especial towards engineered-viral therapy to provide additional modalities of treatment associated with enhanced efficacy. Presently, numerous oncolytic viruses for both monotherapy, and combination therapy are undergoing clinical trials to evaluate the safety and efficacy of treatments. One recent study conducted by Hemminki et al. reveals the impact of the oncolytic adenovirus Ad5/3-E2F- delta24-GMSF in inducing oncolysis and initiating a potent anticancer immune response towards solid non-metastatic tumours. The results showed a radiological disease control rate of 83%, and accumulate of immunological cells to tumours in 9/12 patients (A16). However, the monotherapeutic delivery of oncolytic viruses may not serve optimal success for metastatic and advanced stages of cancer. Thereby, oncolytic viruses can be combined with other anticancer remedies to maximized the efficacy of therapeutics in a synergetic manner. A study conducted by Cerullo et al. demonstrates the immunological effects of cyclophosphamide (CP) in combination with oncolytic adenovirus on cancer patients. The results show that CP-adenoviral treatments had higher rates of disease control than that of the virus alone, as well as overall patient-survivability (A17). | + | Current research has progressively contributed to the advancement of breast cancer treatment. The investigations have been especial towards engineered-viral therapy to provide additional modalities of treatment associated with enhanced efficacy. Presently, numerous oncolytic viruses for both monotherapy, and combination therapy are undergoing clinical trials to evaluate the safety and efficacy of treatments. One recent study conducted by Hemminki et al. reveals the impact of the oncolytic adenovirus Ad5/3-E2F- delta24-GMSF in inducing oncolysis and initiating a potent anticancer immune response towards solid non-metastatic tumours. The results showed a radiological disease control rate of 83%, and accumulate of immunological cells to tumours in 9/12 patients <sup>[22]</sup>. However, the monotherapeutic delivery of oncolytic viruses may not serve optimal success for metastatic and advanced stages of cancer. Thereby, oncolytic viruses can be combined with other anticancer remedies to maximized the efficacy of therapeutics in a synergetic manner. A study conducted by Cerullo et al. demonstrates the immunological effects of cyclophosphamide (CP) in combination with oncolytic adenovirus on cancer patients. The results show that CP-adenoviral treatments had higher rates of disease control than that of the virus alone, as well as overall patient-survivability <sup>[7]</sup>. |
| - | Apart from oncolytic therapies, natural killer (NK) cells have also been a significant focus in the field of immunology due to its role in cancer immunosurveillance and potential to eradicate cancer cells. A recent study conducted by Shenouda et al. demonstrates ex-vivo expansion of activated NK-cells in providing highly effective cytotoxicity against breast cancer cell lines (A18). The ability to accumulate personalized activated NK-cells would enable patients to restore or boost NK-cell levels to optimally combat cancerous cells. Ultimately, these findings may offer various modalities of management for more individualized approaches to breast cancer patients, as well as bridging the next step of innovation towards cancer treatment. | + | Apart from oncolytic therapies, natural killer (NK) cells have also been a significant focus in the field of immunology due to its role in cancer immunosurveillance and potential to eradicate cancer cells. A recent study conducted by Shenouda et al. demonstrates ex-vivo expansion of activated NK-cells in providing highly effective cytotoxicity against breast cancer cell lines <sup>[44]</sup>. The ability to accumulate personalized activated NK-cells would enable patients to restore or boost NK-cell levels to optimally combat cancerous cells. Ultimately, these findings may offer various modalities of management for more individualized approaches to breast cancer patients, as well as bridging the next step of innovation towards cancer treatment. |
| ---- | ---- | ||
| - | |||
